Flapless Emdogain in the Treatment of Periodontal Residual Pockets

The Use of Flapless Enamel Matrix Derivative in Treating Periodontal Residual Pockets: A Single-centre Randomized Clinical Trial

48 adult patients participated in a single-centre randomized clinical trial with split- mouth design. They had presented at re-evaluation after initial non-surgical periodontal therapy (steps 1 and 2 of periodontal therapy) for generalized periodontitis with at least 2 teeth with residual probing pocket depths (PPD) ≥5 and ≤8 mm, with bleeding on probing (BOP). Two teeth with similar PPD were randomized to receive re-instrumentation either with (test) or without (control) adjunctive flapless administration of EMD. Differences in the changes of PPD and BOP from baseline to 6 and 12 months will be analysed, and the frequencies of pocket closure (PPD ≤4 mm and no BOP) will be compared

Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD

Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application

Inclusion Criteria: at least two residual pockets with probing pocket depth (PPD) ≥5 and ≤8 mm, bleeding on probing (BOP), mobility ≤degree 1 and no furcation involvement. Exclusion Criteria: full mouth plaque score >20%, uncontrolled systemic disease, history of malignant disease in the oral cavity or previous radiotherapy in the head or neck area, pregnant or lactating females, drug and alcohol abuse, smoking >10 cigarettes per day and inadequate restorative therapy or malocclusion.